Mean±95% CI tests and procedures by NYHA class (excluding interventionalists)
| Topic | NYHA class I | NYHA class II | NYHA class III | NYHA class IV |
| Number of Echos performed per annum, n | 8 | 8 | 8 | 8 |
| Mean±95% CI | 0.64±0.26 | 0.78±0.32 | 1.69±0.72 | 1.31±0.45 |
| Number of stress-induced Echos performed per annum, n | 8 | 8 | 8 | 7 |
| Mean±95% CI | 0.01±0.02 | 0.33±0.23 | 0.65±0.27 | 0.07±0.14 |
| Number of resting Echos performed per annum, n | 8 | 8 | 8 | 8 |
| Mean±95% CI | 0.58±0.24 | 0.66±0.27 | 1.50±0.52 | 1.13±0.40 |
| Number of 12-lead ECGs performed per annum, n | 8 | 8 | 8 | 8 |
| Mean±95% CI | 0.73±0.25 | 0.94±0.39 | 2.13±1.01 | 3.13±2.01 |
| Number of cardiac MRI tests performed per annum, n | 8 | 8 | 8 | 8 |
| Mean±95% CI | 0.10±0.12 | 0.13±0.12 | 0.34±0.29 | 0.29±0.31 |
| Number of ambulatory 24–48 hour ECG (Holter) tests performed per annum, n | 8 | 8 | 8 | 8 |
| Mean±95% CI | 0.70±0.44 | 0.76±0.44 | 1.07±0.44 | 0.85±0.56 |
| Number of CPETs performed per annum, n | 8 | 8 | 8 | 8 |
| Mean±95% CI | 0.19±0.26 | 0.21±0.25 | 0.25±0.24 | 0.14±0.24 |
| Number of BNP or NT-proBNP tests performed per annum, n | 8 | 8 | 8 | 8 |
| Mean±95% CI | 0.26±0.32 | 0.36±0.30 | 0.91±0.55 | 1.63±1.06 |
| Number of troponin T/I tests performed per annum, n | 8 | 8 | 8 | 8 |
| Mean±95% CI | 0.13±0.24 | 0.25±0.32 | 0.61±0.48 | 1.26±1.15 |
| Proportion of patients in the obstructive HCM population who are in receipt of a cardiac implantable defibrillator device, %* | 8 | 8 | 8 | 7 |
| Mean±95% CI | 6.31±3.86 | 12.13±7.37 | 15.13±8.03 | 17.57±9.68 |
| Proportion of patients in the obstructive HCM population who are in receipt of a cardiac implantable pacemaker device, %† | 8 | 8 | 8 | 8 |
| Mean±95% CI | 0.63±0.52 | 2.19±1.26 | 6.44±5.60 | 8.50±6.38 |
| Proportion of patients in the obstructive HCM population who will undergo SRT, %‡ | 7 | 8 | 8 | 7 |
| Mean±95% CI | 0±N/A§ | 2.00±1.74 | 17.25±7.19 | 2.71±2.76 |
| Proportion of patients in the obstructive HCM population who will undergo alcohol septal ablation, % | 7 | 8 | 8 | 7 |
| Mean±95% CI | 0±N/A§ | 1.38±1.38 | 6.88±3.38 | 2.57±2.77 |
| Proportion of patients in the obstructive HCM population who will undergo a septal myectomy, % | 7 | 8 | 8 | 7 |
| Mean±95% CI | 0±N/A§ | 0.63±0.98 | 10.38±6.64 | 0.29±0.56 |
| Proportion of patients in the obstructive HCM population who underwent SRT who are likely to have a complication because of the procedure, % | 7 | 7 | 7 | 8 |
| Mean±95% CI | 1.00±1.42 | 3.14±4.11 | 10.83±8.82 | 20.00±14.98 |
| Proportion of patients in the obstructive HCM population who are likely to have cardiac rehabilitation procedures, % | 6 | 8 | 8 | 6 |
| Mean±95% CI | 0.00±N/A | 6.88±12.14 | 16.25±23.92 | 2.17±3.22 |
| Length of cardiac rehabilitation procedure, weeks | 0 | 3 | 3 | 1 |
| Mean±95% CI | – | 2.75±2.45 | 3.33±3.46 | 4.00±N/A§ |
Each question refers to the number of tests/procedures the experts estimated each patient with obstructive HCM undergoes on average per annum, the proportion of patients who will receive a device or undergo therapy, or the average length of a cardiac rehabilitation procedure in weeks. Unless otherwise specified, eight experts responded to each question in this section.
*Includes ICDs and CRT-Ds only.
†Includes pacemakers and CRT-Ps only.
‡Includes alcohol septal ablation and/or myectomy.
§CI was not relevant because the variance was 0.
BNP, B-type natriuretic peptide; CPET, cardiopulmonary exercise test; CRT-D, cardiac resynchronisation therapy-defibrillator; CRT-P, cardiac resynchronisation therapy-pacemaker; Echo, echocardiogram; HCM, hypertrophic cardiomyopathy; ICD, implantable cardioverter-defibrillator; N/A, not available; NT-proBNP, N-terminal pro B-type natriuretic peptide; NYHA, New York Heart Association; SRT, septal reduction therapy.